At 54 weeks in the STOP-HS1 and STOP-HS2 trials, up to 71.4% of patients taking povorcitinib achieved at least a 50% reduction from baseline in the total abscess and inflammatory ...

While urethral diseases are less frequent than other urinary tract pathologies, periurethral abscesses represent a critical ...

London curator Ekow Eshun shares his vision for the 2027 SITE Santa Fe International Biennial ...

Bimekizumab at different dosing intervals was associated with greater IHS4 improvements at week 48 than placebo in patients with HS.

Different doses lead to different effects on the body and the brain ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

What started as a simple toothache for a Mid-South woman quickly turned into a life-threatening medical emergency, ...

Among the most striking findings, 86.1% of patients treated with bimekizumab were completely flare-free across the entire ...

As president of the Stanford Medicine Outreach Program, I lead a group of medical students and volunteer clinicians; we ...

This is the first in a series from Dr. Scott Hamilton, director of the Pediatric Emergency Department at Ochsner Lafayette ...

Hives can seem random because they erupt fast, move fast, and often vanish before anyone else sees them. One welt may itch ...

A hidden waste-removal pathway in the brain has finally been caught in action. Using cutting-edge MRI scans, researchers ...